News & Events

Researchers Find Potential Link Between Genetic Mutations and Treatment Resistance in Patients With Relapsed or Refractory Multiple Myeloma 

“Treatment of relapsed multiple myeloma can be extremely difficult despite the tremendous progress we have made,” said Hearn Jay Cho, MD, PhD, Chief Medical Officer of the MMRF. “Uncovering new targets and therapies that act upon them may be helpful in the future for patients who develop resistance to current treatment such as CD38-targeting monoclonal antibodies….”

*Read more at The ASCO Post*